logo

For the Inventor, By the Inventor

Paris, France

Cellectis


USPTO Granted Patents = 100

% Expired Patents = 13.0



Trademarks = 3

Forward Citations = 419

Loading Chart...
Loading Chart...

79 inventors (with patents filed for the assignee):

goldMedal Philippe Duchateau (44 out of 54 patents)

silverMedal Laurent Poirot (38 out of 39 patents)

bronzeMedal Roman Galetto (22 out of 27 patents)

4.  Julianne Smith (21 out of 23 patents)

5.  Andrew M Scharenberg (18 out of 47 patents)

6.  Julien Valton (16 out of 19 patents)

7.  Agnes Gouble (14 out of 14 patents)

8.  Alexandre Juillerat (12 out of 19 patents)

9.  Stephanie Grosse (11 out of 11 patents)

10.  Cecile Mannioui (9 out of 9 patents)

11.  Jean-Pierre Cabaniols (8 out of 8 patents)

12.  David Sourdive (7 out of 7 patents)

13.  Jean-Charles Epinat (7 out of 12 patents)

14.  André Choulika (6 out of 11 patents)

15.  Cécile Schiffer-Mannioui (6 out of 6 patents)


Core Competencies:
Chimeric Antigen Receptors
Gene Editing
T Cell Engineering
Immunotherapy
Cancer Treatment
CRISPR Technology
T Cell Resistance
Targeted Gene Insertion
Allogeneic T Cells
Immune Cell Therapy
Tumor Microenvironment

100 patents:

1. 12680076 - METHODS FOR ENGINEERING ALLOGENEIC AND HIGHLY ACTIVE T CELL FOR IMMUNOTHERAPHY (2026-07-14),
2. 12655451 - TAL- effector nuclease (TALEN) -MODIFIED ALLOGENIC CELLS SUITABLE FOR THERAPY (2026-06-16),
3. 12577581 - USE OF PRE T ALPHA OR FUNCTIONAL VARIANT THEREOF FOR EXPANDING TCR ALPHA DEFICIENT T CELLS (2026-03-17),
4. 12391933 - Targeted gene insertion for improved immune cells therapy (2025-08-19),
5. 12365733 - Method for improving production of car T cells (2025-07-22),
6. 12252699 - Method for generating t-cells compatible for allogenic transplantation (2025-03-18),
7. 12221478 - Targeted gene integration of CRS inhibitor genes for improved immune cells therapy (2025-02-11),
8. 12209125 - Targeted gene integration of NK inhibitors genes for improved immune cells therapy (2025-01-28),
9. 12171820 - Method for generating immune cells resistant to arginine and/or tryptophan depleted microenvironment (2024-12-24),
10. 12144825 - Cellular immunotherapy for repetitive administration (2024-11-19),
11. 12012607 - Engineering wheat with increased dietary fiber (2024-06-18),
12. 11987639 - Trophoblast glycoprotein (5T4, TPBG) specific chimeric antigen receptors for cancer immunotherapy (2024-05-21),
13. 11959091 - Methods for engineering T cells for immunotherapy by using RNA-guided Cas nuclease system (2024-04-16),
14. 11919961 - CD123 specific chimeric antigen receptors for cancer immunotherapy (2024-03-05),
15. 11903968 - Engineered immune cells resistant to tumor microenvironment (2024-02-20),
Cellectis is a biotechnology company that specializes in gene editing and the development of innovative CAR-T cell therapies for cancer treatment. With headquarters in Paris, France, and offices in New York, USA, Cellectis aims to revolutionize the field of immuno-oncology by providing highly personalized and off-the-shelf gene-edited CAR-T therapies. Their advanced technologies, such as TALEN® and MegaTAL™, enable precise and efficient gene modifications, offering new possibilities for the treatment of various cancers.
This text is generated by artificial intelligence and may not be accurate.

logo

Company Badge

USPTO Data Jan 1 1976 - Sep 29 2026

Cellectis
100 Patents

#80 in Paris

#273 in France

#7,768 in the World

Paris, FR
Paris, France

Cellectis

Forward Citations = 419

79 inventors:

goldMedal Philippe Duchateau (44 out of 54 patents)

silverMedal Laurent Poirot (38 out of 39 patents)

bronzeMedal Roman Galetto (22 out of 27 patents)

4.  Julianne Smith (21 out of 23 patents)

5.  Andrew M Scharenberg (18 out of 47 patents)

Please report any incorrect information to [email protected]
Loading…